{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:58:56Z","timestamp":1792087136131,"version":"4.4.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background and Aim<\/jats:title>\n                    <jats:p>Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat fever, pain, and inflammation. Concerns regarding their cardiovascular safety have been raised. However, the underlying mechanism behind these events remains unknown. We aim to investigate the cardiovascular safety signals and receptor mechanisms of NSAIDs, employing a comprehensive approach that integrates pharmacovigilance and pharmacodynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study utilized a pharmacovigilance-pharmacodynamic approach to evaluate the cardiovascular safety of NSAIDs and explore potential receptor mechanisms involved. Data were analyzed using the OpenVigil 2.1 web application, which grants access to the FDA Adverse Event Reporting System (FAERS) database, in conjunction with the BindingDB database, which provides target information on the pharmacodynamic properties of NSAIDs. Disproportionality analysis employing the Empirical Bayes Geometric Mean (EBGM) and Reporting Odds Ratio (ROR) methods was conducted to identify signals for reporting cardiovascular-related adverse drug events (ADEs) associated with 13 NSAIDs. This analysis encompassed three System Organ Classes (SOCs) associated with the cardiovascular system: blood and lymphatic system disorders, cardiac disorders, and vascular disorders. The primary targets were identified through the receptor-NSAID interaction network. Ordinary least squares (OLS) regression models explored the relationship between pharmacovigilance signals and receptor occupancy rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 201,231 reports of cardiovascular-related ADEs were identified among the 13 NSAIDs. Dizziness, anemia, and hypertension were the most frequently reported Preferred Terms (PTs). Overall, nimesulide and parecoxib exhibited the strongest signal strengths of ADEs at SOC levels related to the cardiovascular system. On the other hand, our data presented naproxen and diclofenac as drugs of comparatively low signal strength. Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) were identified as central targets. OLS regression analysis revealed that the normalized occupancy rate for either COX-1 or COX-2 was significantly inversely correlated with the log-transformed signal measures for blood and lymphatic system disorders and vascular disorders, and positively correlated with cardiac disorders and vascular disorders, respectively. This suggests that higher COX-2 receptor occupancy is associated with an increased cardiovascular risk from NSAIDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cardiovascular safety of NSAIDs may depend on pharmacodynamic properties, specifically, the percentage of the occupied cyclooxygenase isoenzymes. More studies are needed to explore these relations and improve the prescription process.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1455212","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:35:17Z","timestamp":1725410117000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs"],"prefix":"10.3389","volume":"15","author":[{"given":"Shuang","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11695-018-3608-y","article-title":"Safety and efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) used for analgesia after bariatric surgery: a retrospective case-control study","volume":"29","author":"Abou Zeid","year":"2019","journal-title":"Obes. Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s10787-019-00621-5","article-title":"Dose-dependency of the cardiovascular risks of non-steroidal anti-inflammatory drugs","volume":"27","author":"Ahmed","year":"2019","journal-title":"Inflammopharmacology"},{"key":"B3","first-page":"U1755","article-title":"Increased risk of cardiovascular events with parecoxib\/valdecoxib: a systematic review and meta-analysis","volume":"118","author":"Aldington","year":"2005","journal-title":"N. Z. Med. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"j1909","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00296-024-05584-7","article-title":"Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study","volume":"44","author":"Bech-Drewes","year":"2024","journal-title":"Rheumatol. Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"114147","DOI":"10.1016\/j.bcp.2020.114147","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective","volume":"180","author":"Bindu","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.cjca.2021.06.014","article-title":"Recategorization of non-aspirin nonsteroidal anti-inflammatory drugs according to clinical relevance: abandoning the traditional NSAID terminology","volume":"37","author":"Bonnesen","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.semarthrit.2019.07.012","article-title":"Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication","volume":"50","author":"Braun","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"B9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40256-016-0212-1","article-title":"Rates of nonsteroidal anti-inflammatory drug use in patients with established cardiovascular disease: a retrospective, cross-sectional study from NHANES 2009-2010","volume":"17","author":"Castelli","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/schbul\/sbaa163","article-title":"Exploring a safety signal of antipsychotic-associated pneumonia: a pharmacovigilance-pharmacodynamic study","volume":"47","author":"Cepaityte","year":"2021","journal-title":"Schizophr. Bull."},{"key":"B11","doi-asserted-by":"publisher","first-page":"115300","DOI":"10.1016\/j.psychres.2023.115300","article-title":"Cardiovascular toxicity induced by SSRIs: analysis of spontaneous reports submitted to FAERS","volume":"326","author":"Chen","year":"2023","journal-title":"Psychiatry Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"CD007400","DOI":"10.1002\/14651858.CD007400.pub3","article-title":"Topical NSAIDs for chronic musculoskeletal pain in adults","volume":"4","author":"Derry","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14740338.2021.1965988","article-title":"Gastrointestinal and cardiovascular adverse events associated with NSAIDs","volume":"21","author":"Domper Arnal","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","article-title":"COX-2 inhibitors and cardiovascular risk","volume":"50","author":"Funk","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e16780","DOI":"10.1371\/journal.pone.0016780","article-title":"NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies","volume":"6","author":"Garc\u00eda Rodr\u00edguez","year":"2011","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.296.13.jed60058","article-title":"COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense","volume":"296","author":"Graham","year":"2006","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J. Clin. Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"D1091","DOI":"10.1093\/nar\/gkx1121","article-title":"The IUPHAR\/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY","volume":"46","author":"Harding","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/00005344-200605001-00007","article-title":"COX-2 and the kidney","volume":"47","author":"Harris","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.yrtph.2014.09.007","article-title":"Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database","volume":"70","author":"Hunt","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e5768","DOI":"10.1002\/pds.5768","article-title":"Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review","volume":"33","author":"Jiao","year":"2024","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tips.2004.02.012","article-title":"Principles: receptor theory in pharmacology","volume":"25","author":"Kenakin","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.3390\/ijms20174262","article-title":"Cyclo-Oxygenase (COX) inhibitors and cardiovascular risk: are non-steroidal anti-Inflammatory drugs really anti-inflammatory?","volume":"20","author":"Khan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.amjmed.2013.08.017","article-title":"NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease","volume":"127","author":"Kohli","year":"2014","journal-title":"Am. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e006874","DOI":"10.1161\/JAHA.117.006874","article-title":"Comparative risk of cardiovascular outcomes between topical and oral nonselective NSAIDs in Taiwanese patients with rheumatoid arthritis","volume":"6","author":"Lin","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/annrheumdis-2012-203137","article-title":"Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study","volume":"73","author":"Lindhardsen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"12231","DOI":"10.1038\/s41598-024-62852-z","article-title":"Adverse events reporting of XPO1 inhibitor - selinexor: a real-word analysis from FAERS database","volume":"14","author":"Liu","year":"2024","journal-title":"Sci. Rep."},{"key":"B30","first-page":"24","article-title":"Recognizing the risks of chronic nonsteroidal anti-inflammatory drug use in older adults","volume":"18","author":"Marcum","year":"2010","journal-title":"Ann. Longterm. Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.2459\/JCM.0000000000000443","article-title":"NSAIDs and cardiovascular risk","volume":"18","author":"Marsico","year":"2017","journal-title":"J. Cardiovasc. Med. Hagerst."},{"key":"B32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jcph.1302","article-title":"Cardiovascular risk of nonsteroidal anti-inflammatory drugs and classical and selective cyclooxygenase-2 inhibitors: a meta-analysis of observational studies","volume":"59","author":"Mart\u00edn Arias","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.pmn.2018.01.008","article-title":"Older adults\u2019 response to analgesic adverse drug reactions: a pilot study","volume":"19","author":"McDonald","year":"2018","journal-title":"Pain Manag. Nurs."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies","volume":"8","author":"McGettigan","year":"2011","journal-title":"PLoS Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.rdc.2022.08.006","article-title":"Recommendations for the use of nonsteroidal anti-inflammatory drugs and cardiovascular disease risk: decades later, any new lessons learned?","volume":"49","author":"Minhas","year":"2023","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"B36","doi-asserted-by":"publisher","first-page":"107624","DOI":"10.1016\/j.pharmthera.2020.107624","article-title":"Cyclooxygenases and the cardiovascular system","volume":"217","author":"Mitchell","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.euroneuro.2015.07.010","article-title":"Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase","volume":"25","author":"Montastruc","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/clc.22814","article-title":"Cardiovascular safety of NSAIDs: additional insights after PRECISION and point of view","volume":"40","author":"Pepine","year":"2017","journal-title":"Clin. Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/rheumatology\/kel428","article-title":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study","volume":"46","author":"Rahme","year":"2007","journal-title":"Rheumatol. Oxf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1177\/0269881117722987","article-title":"Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment","volume":"31","author":"Reynolds","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/j.1552-4604.1995.tb04050.x","article-title":"Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis","volume":"35","author":"Schafer","year":"1995","journal-title":"J. Clin. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/jez.2554","article-title":"Cardiovascular serotonergic system: evolution, receptors, transporter, and function","volume":"337","author":"Soslau","year":"2022","journal-title":"J. Exp. Zool. A Ecol. Integr. Physiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/joim.13505","article-title":"Lessons from 20 years with COX-2 inhibitors: importance of dose-response considerations and fair play in comparative trials","volume":"292","author":"Stiller","year":"2022","journal-title":"J. Intern. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.2174\/138161206778194051","article-title":"Kinins and cardiovascular diseases","volume":"12","author":"Su","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"B47","first-page":"77","article-title":"An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID consensus participants","volume":"155","author":"Tannenbaum","year":"1996","journal-title":"CMAJ"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1144","DOI":"10.7759\/cureus.1144","article-title":"Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue","volume":"9","author":"Varga","year":"2017","journal-title":"Cureus"},{"key":"B49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12325-019-01144-9","article-title":"Ibuprofen safety at the golden anniversary: are all NSAIDs the same? A narrative review","volume":"37","author":"Varrassi","year":"2020","journal-title":"Adv. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00228-014-1734-6","article-title":"Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects","volume":"70","author":"Wehling","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14336\/AD.2017.0306","article-title":"A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly","volume":"9","author":"Wongrakpanich","year":"2018","journal-title":"Aging Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3892\/ijo.2018.4578","article-title":"Effects of non-steroidal anti-inflammatory drug-activated gene-1 on Ganoderma lucidum polysaccharides-induced apoptosis of human prostate cancer PC-3 cells","volume":"53","author":"Wu","year":"2018","journal-title":"Int. J. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1455212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:35:23Z","timestamp":1725410123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1455212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":53,"alternative-id":["10.3389\/fphar.2024.1455212"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1455212","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"article-number":"1455212"}}